The U. Food and Drug Administration FDA is strengthening existing warnings about serious behavior and mood-related changes with montelukast Singulair and generics , which is a prescription medicine for asthma and allergy. We are taking this action after a review of available information led us to reevaluate the benefits and risks of montelukast use. We decided a stronger warning is needed after conducting an extensive review of available information and convening a panel of outside experts , and therefore determined that a Boxed Warning was appropriate.
Back to Medicines A to Z. Montelukast is used to prevent the symptoms of asthma. It's usually prescribed when asthma is mild and can stop it from getting worse. It can also help people with asthma who have breathing difficulties when they exercise exercise-induced asthma and seasonal allergies, such as sneezing, itchiness and a blocked or runny nose allergic rhinitis. Montelukast is sometimes given to people without asthma to treat hives urticaria that last for a long time more than 6 weeks. Most people take montelukast once a day in the evening to prevent asthma or allergy symptoms.
Background: Severe asthma remains a worldwide medical problem. However, this disease has not been adequately explored in the elderly. This study was performed to determine how the addition of montelukast to antiasthmatic therapy improves the control of severe asthma in elderly patients. The primary efficacy endpoint of the study was the percentage of days without asthma symptoms in the first 12 months of treatment compared with the percentage after adding montelukast therapy.
The aim of this study was to determine the efficacy and safety of montelukast added to previous medication in the treatment of a mild and moderate asthma. Data were obtained via questionnaires given to the physicians and given further to their patients. Patients were divided in two groups, first followed 4 weeks patients and second followed 8 weeks 91 patients. We found out that there was a significant improvement in FEV1 forced expiratory volume in first second and general condition of patients and decreased number of salbutamol inhalations after using montelukast.